News

February 6, 2019February 6, 2019

FDA Expands Alimta’s Label for Initial Treatment of Metastatic Lung Cancer

News

The U.S. Food and Drug Administration has expanded Alimta‘s (pemetrexed) label to include a combination with Keytruda (pembrolizumab) and platinum chemotherapy for the initial treatment of certain metastatic non-small cell lung cancer (NSCLC) patients. ... Read more

February 5, 2019February 5, 2019

Phase 1b Trial of ADCT-301 in Advanced Solid Tumors Doses First Patient

News

A Phase 1b clinical trial of ADCT-301 (camidanlumab tesirine) in adult patients with locally advanced or metastatic solid tumors has dosed the first patient. Patient enrollment for this multicenter, open-label ... Read more

February 1, 2019February 1, 2019

Tumors with More Mutations Respond Better to Immunotherapy, Study Suggests

News

A new study suggests that tumors with more mutations respond better to immunotherapy. But determining what constitutes a “high” number of mutations in a given tumor type, and implementing information as ... Read more

January 30, 2019January 30, 2019

Nanobiotix Plans Nine NBTXR3 Clinical Trials for Six Cancer Types

News

Nanobiotix is planning to conduct nine Phase 1/2 clinical trials in collaboration with the University of Texas MD Anderson Cancer Center to study the company’s investigational compound NBTXR3. The trials, which will include ... Read more

January 29, 2019January 29, 2019

Keytruda Reduces Risk of Death in Some Patients with Advanced Esophageal Cancer, Study Shows

News

Second-line treatment with Keytruda (pembrolizumab) significantly extends the lives of advanced esophageal cancer and esophagogastric junction carcinoma patients whose tumors are positive for the PD-L1 factor, a Phase 3 clinical trial ... Read more

January 25, 2019January 25, 2019

Opdivo-Yervoy Combo Approved in Europe for First-line Treatment of Certain Kidney Cancers

News

The European Commission has approved a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) for the initial treatment of advanced renal cell carcinoma patients with intermediate and poor risk, making ... Read more

January 23, 2019January 23, 2019

FDA to Review Tecentriq Triple Combo as First-Line Treatment for Certain NSCLC Patients

News

The U.S. Food and Drug Administration will review Genentech‘s Tecentriq (atezolizumab), in combination with chemotherapy medications Abraxane (nab-paclitaxel) and carboplatin, as a first-line treatment for metastatic non-squamous non-small cell lung cancer (NSCLC), the company announced. ... Read more

January 22, 2019January 22, 2019

First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer

News

A Phase 3 clinical trial evaluating the immune checkpoint inhibitor Tyvyt (sintilimab injection), in combination with the chemotherapies Taxol (paclitaxel) and Platinol (cisplatin), as a first-line treatment for esophageal squamous cell carcinoma has started ... Read more

January 18, 2019

New Collaboration Aims to Identify Biomarkers of Bladder Cancer Progression, Immunotherapy Response

News

A new collaboration between GeneCentric Therapeutics and researchers at the University of North Carolina at Chapel Hill is aimed at further understanding bladder cancer patients’ responses to immunotherapies. Moreover, researchers hope to ... Read more

January 16, 2019

AbbVie, Tizona Collaborating on Development of New CD39-targeted Immunotherapies

News

AbbVie and Tizona Therapeutics are partnering to develop immunotherapies that could reshape the tumor microenvironment and enhance immune responses against cancer cells. The agreement is intended to develop new CD39-targeted ... Read more